Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Change in Acquisitions & Divestments (2021 - 2025)

Avidity Biosciences (RNA) has disclosed Change in Acquisitions & Divestments for 5 consecutive years, with $223.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments fell 5.54% year-over-year to $223.6 million, compared with a TTM value of $1.1 billion through Dec 2025, up 85.24%, and an annual FY2025 reading of $1.1 billion, up 85.24% over the prior year.
  • Change in Acquisitions & Divestments was $223.6 million for Q4 2025 at Avidity Biosciences, down from $269.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $330.2 million in Q1 2025 and bottomed at $3.0 million in Q4 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $136.2 million, with a median of $103.5 million recorded in 2023.
  • The sharpest move saw Change in Acquisitions & Divestments soared 2657.67% in 2022, then dropped 5.54% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $3.0 million in 2021, then skyrocketed by 2657.67% to $82.7 million in 2022, then grew by 27.78% to $105.7 million in 2023, then surged by 123.96% to $236.7 million in 2024, then dropped by 5.54% to $223.6 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for RNA at $223.6 million in Q4 2025, $269.6 million in Q3 2025, and $262.8 million in Q2 2025.